Catalent Pharma Solutions has agreed to acquire the Clinical Trial Supplies business of Aptuit for cash consideration of $410 million on a cash and debt free basis. The acquisition will substantially expand Catalent's Development & Clinical Services business, transforming it into the #2 provider globally in clinical supply solutions, and adding important development and clinical manufacturing expertise and capacity. Following the close of the transaction, Aptuit will focus on its market-leading integrated discovery to mid-phase development business.
"This transaction builds important expertise, scale and capability for our Development & Clinical Services business to better meet our customers' needs globally," said John Chiminski, President and CEO of Catalent.
"Focusing on our expertise in discovery and development services leverages our leadership position, and allows us to concentrate on delivering high-growth, high-value scientific services from discovery to mid-phase development,” said Timothy C. Tyson, chairman and CEO of Aptuit.